In April 2026, NASAs Office of the Chief Health and Medical Officer (OCHMO) initiated a working group to review updated VTE case information, additional data gathered revealing altered blood flow status within a cohort of astronauts, and discuss progress of research and clinical activities intended to mitigate the risk of VTE during spaceflight with new []
In April 2026, NASAs Office of the Chief Health and Medical Officer (OCHMO) initiated a working group to review updated VTE case information, additional data gathered revealing altered blood flow status within a cohort of astronauts, and discuss progress of research and clinical activities intended to mitigate the risk of VTE during spaceflight with new []
Share this Article
Recommended